These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 30312729)
1. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade. Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729 [TBL] [Abstract][Full Text] [Related]
2. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623 [TBL] [Abstract][Full Text] [Related]
3. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care. Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267 [TBL] [Abstract][Full Text] [Related]
5. Transcription factor IKZF1 is degraded during the apoptosis of multiple myeloma cells induced by kinase inhibition. Liu Y; He X; Sui Y; Yu R; Xu G FEBS Lett; 2015 Aug; 589(17):2233-40. PubMed ID: 26183205 [TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678 [TBL] [Abstract][Full Text] [Related]
7. Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide. Abdulkarim H; Zourob M; Siaj M Sci Rep; 2020 Jun; 10(1):10424. PubMed ID: 32591583 [TBL] [Abstract][Full Text] [Related]
8. c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma. Osada N; Kikuchi J; Iha H; Yasui H; Ikeda S; Takahashi N; Furukawa Y Clin Transl Med; 2023 Aug; 13(8):e1364. PubMed ID: 37581569 [TBL] [Abstract][Full Text] [Related]
9. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Cervantes-Gomez F; Chen LS; Orlowski RZ; Gandhi V Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S317-29. PubMed ID: 23988451 [TBL] [Abstract][Full Text] [Related]
10. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725 [TBL] [Abstract][Full Text] [Related]
11. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969 [TBL] [Abstract][Full Text] [Related]
12. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557 [TBL] [Abstract][Full Text] [Related]
13. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735 [TBL] [Abstract][Full Text] [Related]
14. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135 [TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939 [TBL] [Abstract][Full Text] [Related]
16. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Krönke J; Udeshi ND; Narla A; Grauman P; Hurst SN; McConkey M; Svinkina T; Heckl D; Comer E; Li X; Ciarlo C; Hartman E; Munshi N; Schenone M; Schreiber SL; Carr SA; Ebert BL Science; 2014 Jan; 343(6168):301-5. PubMed ID: 24292625 [TBL] [Abstract][Full Text] [Related]
17. The paradoxical pharmacological mechanisms of lenalidomide and bortezomib in the treatment of multiple myeloma. Wang B; Duan J; Zhou L Anticancer Drugs; 2021 Mar; 32(3):227-232. PubMed ID: 33534410 [TBL] [Abstract][Full Text] [Related]
18. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages. Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611 [TBL] [Abstract][Full Text] [Related]
19. Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3. Liu XP; He L; Zhang QP; Zeng XT; Liu SQ Med Sci Monit; 2018 May; 24():2809-2817. PubMed ID: 29729093 [TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies. Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]